![]() ![]() ![]() ![]() ![]() |
![]() ![]() ![]() |
![]() ![]() |
![]() |
( 1 of 2 ) |
United States Patent | 7,799,794 |
Kivlighn , et al. | September 21, 2010 |
This invention relates to a method for treating and preventing hypertension by administering a therapeutically effective amount of an agent capable of reducing uric acid levels in a patient in need of such treatment. Additionally, the scope of the invention includes a method of treating coronary heart disease by administering a therapeutically effective amount of an agent capable of reducing uric acid levels in a patient in need of such treatment.
Inventors: | Kivlighn; Salah (Doylestown, PA), Johnson; Richard (Bellaire, TX), Mazzali; Marilda (Houston, TX) |
Assignee: |
Merck Sharp & Dohme Corp.
(Rahway,
NJ)
University of Washington (Seattle, WA) |
Appl. No.: | 09/892,505 |
Filed: | June 28, 2001 |
Application Number | Filing Date | Patent Number | Issue Date | ||
60214825 | Jun., 2000 | ||||
Current U.S. Class: | 514/262.1 ; 514/183; 514/256 |
Current International Class: | A61K 31/519 (20060101) |
Field of Search: | 514/262,264,262.1,183 |
4032522 | June 1977 | Baldwin et al. |
4058614 | November 1977 | Baldwin |
4296122 | October 1981 | Cragoe, Jr. et al. |
4510322 | April 1985 | Blaine et al. |
4539323 | September 1985 | Mentrup et al. |
5260322 | November 1993 | Nakasima et al. |
5747495 | May 1998 | Maeda et al. |
2707269 | Feb., 1977 | DE | |||
2707270 | Feb., 1977 | DE | |||
000128 | Jun., 1978 | EP | |||
0 104483 | Aug., 1983 | EP | |||
0 337 350 | Oct., 1989 | EP | |||
415566 | Jul., 1990 | EP | |||
1 451 029 | Sep., 1976 | GB | |||
WO 93 04688 | Mar., 1993 | WO | |||
WO 00 07629 | Feb., 2000 | WO | |||
Proceedings of the Society for Experimental Biology and Medicine 1996, 211(4), 366-73. cited by examiner . Ward, Lancet 1988, 352, pp. 670-671. cited by examiner . L.M. Burrell, "A risk-benefit assessment of Losartan potassium in the treatment of hypertension", Drug Safety, vol. 16, No. 1, 1997, pp. 56-65. cited by other . T. Gibson E.A.; "Tienilic acid in the treatment of gout and hypertension", Advances in Experimental Medicine and Biology, vol. 122A, 1980 pp. 277-282. cited by other . Wu, X. et al; Two Independent Mutational Events Resulted in the Loss of Urate Oxidase During Hominoid Evolution, J. Mol. Evol.34:78-84 (1992). cited by other . Eaton, S.B. et al; a Consideration of its Nature and Current Implications, N. Engl J Med 312:283-289 (1985). cited by other . Cannon, P.J. et al; Hyperuricemia in Primary and Renal Hypertension, N Engl J Med 275:457-464 (1966). cited by other . Haig, A., On Uric Acid and Arterial Tension, Br Med J 1:288-291 (1889). cited by other . Selby, J.V. et al, Precursors of Essential Hypertension: Pulmonary Function, Heart Rate, Uric Acid, Serum Cholesterol, and Other Serum Chemistries, Am J Epidemiol 131:1017-27 (1990). cited by other . Jossa, F. et al, Erum Uric Acid and Hypertension:The Olivetti Heart Study, J Hum Hypertens 8:677-681 (1994). cited by other . Goldstein, H.S. et al, Relationship Between Serum Uric Acid and Blood Pressure in Adolescents, Annals Hum Biol 20:423-431(1993). cited by other . Fang, J. et al, Serum Uric Acid and Cariovascular Mortality, The NHANES I Epidemiologic Follow-up Study, 1971-1992, JAMA 283:2404-2410 (2000). cited by other . Bengtsson, C. et al, Hyperuricemia and Risk of Cardiovascular Disease and Overall Death, Acta Med Scand 224:549-55 (1988). cited by other . Alderman, M.H. et al, Serum Uric Acid and Cariovascular Events in Successfully Treated Hypertensive Patients, Hypertension 34:144-150 (1999). cited by other . Lehto, S. et al, Serum Uric Acid is a Strong Predictor of Stroke in Patients with Non-Insulin Dependent Diabetes Mellitus, Stroke 29:635-639 (1998). cited by other . Persky, V.W. et al, Uric Acid:A risk Factor for Coronary Heart Disease? Circulation 59:969-979 (1979). cited by other . Vaccarino, V. et al, Risk Factors for Cardiovascular Disease: One Down, Many More to Evaluate, Ann Int Med 131:62-63 (1999). cited by other . Wannamethee, S.G., Is Serum Uric Acid a Risk Factor for Coronary Heart Disease? J Hum Hypertens 13:153-156 (1999). cited by other . R. Grahame et al., "Clinical survey of 354 patients with gout", Arm. Rheum. Dis. (1970), 29, pp. 461-468. cited by other . Bruce F. Culleton, MD, et al., "Serum Uric Acid and Risk for Cardiovascular Disease and Death: The Framingham Heart Study", Ann Intern Med.,1999, 131, pp. 7-13. cited by other . Ronald Klein, MD, et al., Serum Uric Acid: Its Relationship to Coronary Heart Disease Risk Factors and Cardiovascular Disease, Evans, County, Georgia, Arch Intern Med/ vol. 132, Sep. 1973, pp. 401-410. cited by other . Katsuhido Yano, et al., Ten-Year Incidence of Coronary Heart Disease in the Honolulu Heart Program, American Journal of Epidemiology, vol. 119, No. 5, May 1984, pp. 653-665. cited by other . "Chronic cyclosporine nephropathy: The Achilles' heel of immunosuppressive therapy", Kidney International, vol. 50, 1996, pp. 1089-1100. cited by other . Bryan D. Myers et al., "Cyclosporine-Induced Chronic Nephropathy: An Obliterative Microvascular Renal Injury", Journal of the American Society of Nephrology, vol. 2, Supplement 1, 1991, pp. 45-52. cited by other . J.R. Chapman et al., Reversibility of Cyclosporin Nephrotoxicity After Three Months' Treatment, the Lancet, Jan. 19, 1985, pp. 128-129, 308-313. cited by other . Paul R. Gores, M.D., et al., "Hyperuricemia After Renal Transplantation", The American Journal of Surgery, vol. 156, Nov. 1988, pp. 397-400. cited by other . Leslie E. Kahl, M.D. et al., "Gout in the Heart Transplant Recipient: Physiologic Puzzle and Therapeutic Challenge", The American Journal of Medicine, vol. 87, Sep. 1989, pp. 289-294. cited by other . David E.R.Sutherland et al., "Results of the Minnesota Randomized Prospective Trial of Cyclosporine Versus Azathioprine-Antilymphocyte Globulin for Immunosuppression in Renal Allograft Recipients", American Journal of Kidney Diseases, vol. V, No. 6, Jun. 1985, pp. 318-327. cited by other . Cynthia West, MD, et al., "The Incidence of Gout in Renal Transplant Recipients", American Journal of Kidney Disease, vol. X, No. 5, Nov. 1987, pp. 369-371. cited by other . R.M. Zurcher, et al., "Hyperuricaemia in cyclosporin-treated patients: a GFR-related effect", 1996 European Dialysis and Transplant Association-European Renal Association, 1996, 11: pp. 153-158. cited by other . Jarmo Laine, et al., "Mechanisms of Hyperuricemia in Cyclosporine-Treated Renal Transplanted Children", Nephron, 1996, 74: pp. 318-323. cited by other . R. Marcen et al., "Impairment of Tubular Secretion of Urate in Renal Transplant Patients on Cyclosporine", Nephron 1995, 70:, pp. 307-313. cited by other . Bryan D. Myers, "Cyclosoporine nephrotoxicity", Kidney International, vol. 30, 1986, pp. 964-974. cited by other . W.M. Bennett, et al., "Nephrotoxicity of immunosuppressive drugs"., Nephrol Dial Transplant, 1994 9, Supp. 4:, pp. 141-145. cited by other . Emmanuel A. Burdmann, et al., "Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril", The American Physiological Society, 1999, pp. F194-499. cited by other . Raimund H. Pichler.sup.2, et al., "Pathogenesis of Cyclosporine Nephropathy: Roles of Angiotensin II and Osteopontin", Journal of American Society of Nephrology, vol. 6, No. 4, 1995, pp. 1186-1196. cited by other . Peter F. Hoyer, et al., "Renal handling of uric acid under cyclosporin A treatment", Pediatric Nephrology, 1988, 2, pp. 18-21. cited by other . Franz H. Messerli, M.D., et al., "Serum Uric Acid in Essential Hypertension: An Indicator of Renal Vascular Involvement", Annals of Internal Medicine, 1980, 93: pp. 817-821. cited by other . Laurence H. Beck, "Requeim for gouty nephropathy", Kidney International, vol. 30, 1986, pp. 280-287. cited by other . "An evaluation of the pathogenesis of the gouty kidney", Kidney Interntational, vol. 8, 1975, pp. 65-71. cited by other . Richard J. Johnson, M.D., et al. "Reappraisal of the Pathogenesis and Consequences of Hyperuricemia in Hypertension, Cardiovascular Disease, and Renal Disease", American Journal of Kidney Diseases, vol. 33, No. 2, Feb. 1999, pp. 225-234. cited by other . V. Nickeleti et al., "Uric acid nephropathy and end-stage renal disease--Review of a nono-disease", Nephrol Dial Transplant, 1997, 12, pp. 1832-1838. cited by other . Ts'ai-Fan Yu, M.D., "Renal Function in Gout: V. Factors Influencing the Renal Hemodynamics", The American Journal of Medicine, Nov. 1979, vol. 67, pp. 766-771. cited by other . Sonia M. A. Assis.sup.2, et al., L-Arginine and Allopurinol Protect Against Cyclosporine Nephrotoxicity.sup.1, Transplantation, vol. 63, Apr. 27, 1997, vol. 63, pp. 1070-1073. cited by other . Bernhard F. Becker, Towards the Physiological Function of Uric Acid, Free Radical Biology and Medicine, vol. 14, 1993, pp. 615-631. cited by other . Jerry Waisman, M.D., A Preliminary Report of Nephropathy in yperuricemic Rats, Laboratory Investigation, vol. 30, No. 6, 1974, pp. 716-722. cited by other . Harvey C. Gonick, M.D., "The Renal Lesion in Gout", vol. 62, No. 4, Apr. 1965, pp. 667-674. cited by other . Lawrence Berger, M.D., et al., "Renal Function in Gout:IV. An Analysis of 524 Gouty Subjects Including Long-Term Follow-Up Studies*", The American Journal of Medicine, vol. 59, Nov. 1975, pp. 605-613. cited by other . David Greenbaum, M.B., M.R.C.P., "Renal Biopsy in Gout", British Medical Journal, May 27, 1961, pp. 1502-1504. cited by other . Ts'ai-Fan Yu, M.D., et al., "Impaired Renal Function in Gout" Its Association with Hypertensive Vascular Disease and Intrinsic Renal Disease , The American Journal of Medicine, vol. 72, Jan. 1982, pp. 95-100. cited by other . F. Perez-Ruiz, et al., "Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout", Am. Rheum. Dis, 1995, 57, pp. 545-549. cited by other . W. Jeffrey Fessel, M.D., Renal Outcomes of Gout and Hyperuricemia, The American Journal of Mediciine, vol. 67, Jul. 1979, pp. 74-82. cited by other . Alderman, M.H. et al, "Serum Uric Acid and Cariovascular Events in Successfully Treated Hypertensive Patients", Hypertension 34:144-150 (1999). cited by other . Fang, J. et al, "Serum Uric Acid and Cariovascular Mortality", The NHANES I Epidemiologic Follow-up Study, 1971-1992, JAMA 283:2404-2410 (2000). cited by other . Landmesser, U. et al., "Oxidative stress and vascular damage in hypertension", Coronary Artery Disease, Sep. 2001, 12, (6): 455-461. cited by other . Maxwell, Simon et al., "Anti-oxidants--a protective role in cardiovascular disease?", Expert Opinion, Pharmacother., Nov. 2001; 2(11): 1737-1750. cited by other . Nakashima, M., "Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects", Eur J. Clin Pharmacol (1992), 42: 333-335. cited by other . Nakazono, K. et al., "Does superoxide underlie the pathogenisis of hypertension?", Proc. Natl. Acad. Sci., 88: 10045-10048, 1991. cited by other . Pui, Ching-Hon et al., "Recombinant Urate Oxidase for the Prophylaxis or Treatment of Hyperuricemia in Patients With Leukemia or Lymphoma", J. Clin. Oncol., (2001), 19: 697-704. cited by other . Sowers, J.R., "Hypertension, Angiotensis II, and Oxidative Stress", NEJM, 346: (2002), 1999-2001. cited by other . Vaziri, N.D. et al., "Effect of Antioxidant Therapy on Blood Pressure and NO Synthase Expression in Hypertensive Rats", American Heart Association, 36: (2000) 957-964. cited by other . Verdecch ia, P. et al., "Relation Between Serum Uric Acid and Risk of Cardiovascular Disease in Essential Hypertension: The PIUMA Study", American Heart Association, 36: (2000) 1072-1078. cited by other . Wilox, C.S., "Reactive Oxygen Species: Roles in Blood Pressure and Kidney Function", Current Hypertension Reports, 2002, 160-6. cited by other . Miyamoto, Y., et al. "Potentiation of nitric oxide-mediated vasorelaxation by xanthine oxidase inhibitors.", Proceedings of the Society for Experimental Biology and Medicine, Apr. 1996, vol. 211, NR 4, p. 366-373. cited by other. |
![]() ![]() |
![]() ![]() ![]() |